Drug Trial Radar · NCT01982942
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Jul 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
255
Actual
Start
Nov 2013
Primary completion
May 2017
Study completion Dec 2017
Sponsor
- Lead sponsor
- MediciNovaIndustry
- Sponsor type
- Industry
- Collaborators
- National Institutes of Health (NIH); National Institute of Neurological Disorders and Stroke (NINDS); National Multiple Sclerosis Society
- First posted
- Nov 13, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety, tolerability and activity of ibudilast administered twice daily over a 96 week period in subjects with primary or secondary progressive multiple sclerosis who are currently untreated with long-term MS disease modifying therapy (DMT) or who are receiving either glatiramer acetate (GA) or interferon beta-1, any formulation (IFNβ-1A \[Avonex, Rebif\] or IFNβ-1B \[Betaseron, Extavia\]). Study drug or placebo will be administered to a total of 250 male and female subjects from 21 to 65 years old, inclusive, in two treatment groups. Randomization of subjects will be stratified by disease status (primary progressive multiple sclerosis or secondary progressive multiple sclerosis) and immunomodulating therapy status: current use of immunomodulating therapy or no current use of immunomodulating therapy. The study will consist of a screening phase (up to 30 days) followed by a treatment phase (96 weeks) and a follow-up visit (1 month post Week 96 visit). Following the screening phase, subjects who continue to meet entry criteria will be randomly assigned to 1 of 2 treatment groups: doses up to ibudilast 100 mg/day or matching-placebo in a 1:1 ratio. Study drug will be administered twice daily (BID), e.g., ibudilast 50 mg or placebo taken in the morning and evening).
Conditions
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis, Secondary Progressive
Interventions
ibudilastDrug
Subjects randomly assigned to the ibudilast (MN-166) cohort will receive up to 100 mg/day for 96 weeks.
Placebo oral capsuleDrug
Subjects randomly assigned to the placebo cohort will receive placebo oral capsule for 96 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Covariate-adjusted Mean Rate of Change in Brain Atrophy Over 96 Weeks as Measured by Brain Parenchymal Fraction (BPF).Time frame: 96 weeks
- Percentage of Participants With Adverse Events.Time frame: 96 weeks
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of California Davis
Davis, California
University of California Los Angeles
Los Angeles, California
University of Colorado Denver
Denver, Colorado
University of Miami Miller School of Medicine
Miami, Florida
Emory University
Atlanta, Georgia
Northwestern University
Evanston, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Washington University School of Medicine in St Louis
St Louis, Missouri
University at Buffalo, The State University of New York
Buffalo, New York
Cornell Medical College
New York, New York
Columbia University Medical Center
New York, New York
University of Rochester
Rochester, New York
University at Stony Brook, The State University of New York
Stony Brook, New York
University at Upstate, The State University of New York
Syracuse, New York
Montefiore Medical Center
The Bronx, New York
University of Cincinnati, Department of Neurology
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Ohio State University
Columbus, Ohio
Oregon Health and Science University
Portland, Oregon
University of Pittsburgh
Pittsburgh, Pennsylvania
Vanderbilt University
Nashville, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
University of Utah
Salt Lake City, Utah
University of Virginia Charlottesville
Charlottesville, Virginia
Swedish Medical Center - Seattle
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.